Related Party - Gilead Sciences, Inc. - Additional Information (Details) $ / shares in Units, shares in Millions, $ in Millions	1 Months Ended	12 Months Ended
	May 31, 2023 program	Dec. 31, 2024 USD ($) program member $ / shares shares	Dec. 31, 2023 USD ($) program shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) program shares	Dec. 31, 2020 USD ($) shares	Mar. 31, 2024 USD ($)
Related Party Transaction [Line Items]
Issuance of common stock		$ 228.0	$ 25.0
Number of programs, eligible to receive regulatory and commercial milestone payments | program	4		4
Licensing revenue recognized		243.0	$ 108.0	$ 112.0
Receivable from collaboration partners, current		20.0	38.0
Other noncurrent assets		$ 73.0	106.0
Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Other noncurrent assets			6.0
Gilead | Third Stock Purchase Agreement Amendment
Related Party Transaction [Line Items]
Issuance of common stock (in shares) | shares		15.2
Issuance of common stock		$ 320.0
Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares		$ 21.00
Related Party
Related Party Transaction [Line Items]
Percentage of outstanding common stock held		32.60%
Receivable from collaboration partners, current		$ 6.0	20.0
Other noncurrent assets		0.0	6.0
Related Party | Research and Development
Related Party Transaction [Line Items]
Net of recoveries from related party for shared costs		39.0	$ 110.0	132.0
Related Party | General and administrative
Related Party Transaction [Line Items]
Net of recoveries from related party for shared costs		1.0		1.0
Recognized net payments		2.0		2.0
Related Party | Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Collaboration term for current and future clinical programs						10 years
Common Stock Purchase Agreement | Related Party
Related Party Transaction [Line Items]
Issuance of common stock (in shares) | shares			1.0		5.7	6.0
Funds received for stock purchase agreement						$ 200.0
Purchase price of common stock allocation to performance obligation		$ 87.0				91.0
Issuance of common stock			$ 20.0		$ 220.0
Percentage of premium purchase price of common stock		20.00%
Trailing days average closing price		5 days
Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares		$ 33.54
Number of board members | member		3
Common Stock Purchase Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Right to purchase additional outstanding voting common stock percentage		35.00%
Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Option payment upon completion of certain IND-enabling activities		$ 60.0
Option payment upon achievement of certain development milestones		$ 150.0
Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Option continuation payment due upon eighth anniversary of agreement						100.0
Option continuation payment due upon second anniversary of agreement						100.0
Option continuation payment due upon sixth anniversary of agreement						100.0
Option continuation payment due upon fourth anniversary of agreement						100.0	$ 100.0
Upfront cash payment						$ 175.0
Option fee per program for all other programs entering clinical development to exercise option					150.0
Number of research programs | program		2
Licensing revenue recognized		$ 243.0	112.0	$ 107.0
Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Potential regulatory approval milestones payment receivable related to domvanalimab					$ 500.0
Amended Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Number of exercise option to programs | program					3
Option payments received					$ 725.0
Removal of option continuation payment under agreement					$ 100.0
Option payment upon achievement of certain development milestones			$ 150.0
Number of programs, eligible to receive regulatory and commercial milestone payments | program			2,000,000
Amended Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Upfront cash payment			$ 17.5
Number of research programs | program			2
Option payment upon completion of certain IND-enabling activities			$ 45.0
Total upfront cash payment			35.0
Amended Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Regulatory and commercial milestone payments received			$ 375.0